Sign in
Taking people in United StatesNo phase

Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years

Key facts

Who runs it
Kaiser Permanente
Where
Oakland, United StatesSee the site
Trial code
Status
Recruiting
People taking part
1,500,000 people, planned
Started
17 Aug 2023
Expected to end
May 2028
Type of study
Observational, 2 groups
Treatments tested
  • Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4)
  • High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)
Record updated
5 August 2026

Who can take part

Age
65 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Age ≥65 years at the time of influenza vaccination
  • KPNC member at the time of vaccination
  • Receive either aIIV4 or HD-IIV4 at a KPNC facility during the 2023/24 and/or 2024/25 influenza seasons

Who cannot take part

  • Received either aIIV4 or HD-IIV4 in the inpatient setting
  • Age <65 years at the time of influenza vaccination
  • Receive more than one influenza vaccination during a single season period (i.e., 2023/24 or 2024/25 influenza seasons)
  • Receive an influenza vaccination outside of KPNC

This trial is currently available in United States.

  • Kaiser Permanente Northern California (entire region)Oakland, United StatesContact: Amber H. Hyman, PhD, MPHTaking people

About the trial

What the trial wants to find out

This study will evaluate the relative vaccine effectiveness of quadrivalent adjuvanted inactivated influenza vaccine (aIIV4) versus quadrivalent high-dose inactivated influenza vaccine (HD-IIV4) in preventing polymerase chain reaction (PCR)-confirmed influenza and influenza-related outcomes in adults ≥65 years of age during the 2023/24, 2024/25, and 2026/27 influenza seasons. The study is an observational study conducted at Kaiser Permanente Northern California (KPNC), an integrated health care system in the United States.

The 2 groups in the trial

  • Fluad Recipients

    Kaiser Permanente Northern California members aged ≥65 years who receive Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4)

    Treatment: Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4)

  • Fluzone High-Dose Recipients

    Kaiser Permanente Northern California members aged ≥65 years who receive High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)

    Treatment: High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Relative Vaccine Effectiveness of Adjuvanted Inactivated Influenza Vaccine (aIIV) vs High-Dose Inactivated Influenza Vaccine (HD-IIV) for Prevention of Lab-Confirmed Influenza Among Adults ≥65 Years of Age in the United States
Publications
Record updated
5 August 2026